Today: 19.Jun.2021

Alan Waltar, nuclear engineer, Past President of the American Nuclear Society: The majority of our citizens are aware of the contributions of nuclear technology to the production of electricity via commercial nuclear power plants. But most are unaware that the impact of this technology is even greater for non-power applications. The world of medicine, agriculture, and modern industry has been substantially improved by the harnessing of radioisotopes, and new applications continue to make major humanitarian contributions to our quality of life.

Published in USA

The world is full of scientists, medical professionals and engineers who have made tremendous contributions to making the world a lot better AND explaining it to the public in an interesting way. Alan Waltar is one such person. Please take time to read each of the slides in this presentation. There is a lot we can learn.

Published in USA

Australian Nuclear Science and Technology Organisation, ANSTO: On average, every Australian can expect at some stage in their life to have a nuclear medicine procedure that uses a radioisotope for diagnostic or therapeutic purposes. Nuclear medicine uses small amounts of radiation to provide information about a person's body and the functioning of specific organs. The radioisotopes made in cyclotrons complement those made in a reactor. Atoms with extra neutrons in the nucleus are called neutron-rich and are produced in a nuclear reactor. Atoms with extra protons in the nucleus are called neutron-deficient and are produced in a particle accelerator such as a cyclotron. Both types of radioisotopes are needed to service all of Australia's nuclear medical needs.

Rebecca Campbell, writer, Jan Rijn Zeevaart, Necsa radiochemistry: Dr Zeevaart, who is Necsa’s head of radiochemistry, was the corporation’s top creator of intellectual property (IP), in terms of implementable disclosures to the Office of Technology Transfer, over the period April 1, 2011, to March 31, 2018. During this time, he authored or co-authored ten Innovation Disclosures and co-authored six of Necsa’s “patent families”. All these are in the areas of radiopharmaceuticals and radiochemicals.